<DOC>
	<DOCNO>NCT01641393</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy EUR-1008 compare Kreon® treatment exocrine pancreatic insufficiency associate Cystic Fibrosis subject 12 year age old .</brief_summary>
	<brief_title>Safety Efficacy Study 2 Pancreatic Enzymes Treatment Exocrine Pancreatic Insufficiency Cystic Fibrosis .</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>1 . Definitive diagnosis CF base following : One clinical feature consistent CF Either genotype 2 identifiable mutation know cause CF sweat chloride concentration &gt; 60 mEq/L pilocarpine iontophoresis 2 . Pancreatic insufficiency document monoclonal faecal elastase ( FE ) 100 μg/g stool screening ( test result within previous 12 month acceptable ) 3 . Currently receive pancreatic enzyme replacement therapy 4 . Adequate nutritional status base follow : body mass index ( BMI ) &gt; 19 kg/m2 adult subject BMI percentile 10th percentile age adolescent ( 12 17 year age group ) subject 5 . Are clinically stable evidence concomitant illness acute upper low respiratory tract infection require antibiotic 7day interval prior screen precede entry clinical study 1 . Age &lt; 12 year 2 . Known contraindication , hypersensitivity , intolerance pork porcine PEPs 3 . Current uncontrolled diabetes mellitus 4 . History solid organ transplantation 5 . History surgery affect bowel function weight gain</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Exocrine Pancreatic Insufficiency</keyword>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Pancreatic Insufficiency</keyword>
</DOC>